The MTX release profiles were obtained by using simulated physiological media (phosphate buffered saline (PBS) solution 0.1 M) at pH 5.0 and pH 7.4, representing the cancer environment and the physiological pH, respectively. MTX@MIL-100(Fe) NPs and MTX@MIL-100 capsules (10 mg) were suspended in PBS solution (10 mL) and incubated at 37 °C under constant stirring, prepared in triplicate. Samples were removed after 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 24 and 48 h, and an identical volume of fresh PBS was immediately replaced, keeping up the MTX concentration far from saturation.
The release of MTX was quantified in triplicate by UV–Vis spectroscopy (Cary 60 Spectrophotometer; Agilent, Sidney, Australia) at 306 nm.